Atyr PHARMA (ATYR) Expected to Announce Quarterly Earnings on Thursday

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Atyr PHARMA to post earnings of ($0.19) per share for the quarter.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. On average, analysts expect Atyr PHARMA to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Atyr PHARMA Stock Up 3.4 %

NASDAQ:ATYR traded up $0.11 on Tuesday, reaching $3.38. 1,038,054 shares of the stock traded hands, compared to its average volume of 903,113. The company has a market capitalization of $300.34 million, a price-to-earnings ratio of -3.60 and a beta of 0.95. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The company's fifty day simple moving average is $3.32 and its 200 day simple moving average is $3.38.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Friday, March 14th. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Cantor Fitzgerald began coverage on shares of Atyr PHARMA in a report on Monday, January 6th. They set an "overweight" rating on the stock. Finally, Leerink Partners began coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.